Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-primate lentiviral vectors.

Eric M Poeschla1

  • 1Molecular Medicine Program, Departments of Immunology and Medicine, Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA. emp@mayo.edu

Current Opinion in Molecular Therapeutics
|November 7, 2003
PubMed
Summary

Feline and equine lentivirus vectors show promise in preclinical gene therapy models. Further research into lentiviral restriction and vector engineering is crucial for clinical applications in human gene therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAR1 haploinsufficiency and sustained picornaviral RdRp dsRNA synthesis synergize to dysregulate RNA editing and cause multi-system interferonopathy.

mBio·2025
Same author

ADAR1 haploinsufficiency and sustained picornaviral RdRp dsRNA synthesis synergize to dysregulate RNA editing and cause multi-system interferonopathy.

bioRxiv : the preprint server for biology·2025
Same author

Disruption of LEDGF/p75-directed integration derepresses antisense transcription of the HIV-1 genome.

bioRxiv : the preprint server for biology·2024
Same author

Human mRNA in saliva can correctly identify individuals harboring acute infection.

mBio·2023
Same author

The Feline Immunodeficiency Virus Envelope Signal Peptide Is a Tetherin Antagonizing Protein.

mBio·2023
Same author

Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors.

Viruses·2022

Area of Science:

  • Gene therapy
  • Virology
  • Molecular biology

Background:

  • Lentiviral vectors derived from feline and equine lentiviruses demonstrate significant preclinical efficacy.
  • Advancements in understanding lentiviral life cycles are driving vector development.
  • Existing lentiviral vector systems are being engineered for enhanced safety and efficacy.

Purpose of the Study:

  • To review recent advancements in feline and equine lentiviral vector systems.
  • To discuss the role of species-specific lentiviral restriction in pathogenesis and gene therapy.
  • To outline future research directions for applying these vectors in human gene therapy.

Main Methods:

  • Review of current literature on lentiviral vector systems.
  • Analysis of preclinical data from tissue culture, animal, and ex vivo human organ models.
  • Discussion of fundamental virology and species-specific lentiviral restriction mechanisms.

Main Results:

  • Feline and equine lentiviral vectors show strong preclinical results.
  • Species-specific lentiviral restriction is a key factor influencing vector performance and pathogenesis.
  • Development of clinical-grade packaging/producer cell lines is an important goal.

Conclusions:

  • Lentiviral vector systems offer significant potential for human gene therapy.
  • Continued progress in fundamental virology and vector engineering is essential.
  • Rigorous comparison of different lentiviral vector systems in human targets is needed.

Related Experiment Videos